MCL1 and cancer: Second, we found that atuveciclib treatment decreased protein levels of MYC and MCL1 (Figure 2), two major pro-tumorigenic factors regulated by RNA Pol II that are often associated with poor clinical outcomes in many cancer types including TNBC [27, 34].